本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

康乃德生物医药

2.12
+0.440026.19%
盘前2.170.0500+2.36%09:00 EST
成交量:104.36万
成交额:204.89万
市值:1.19亿
市盈率:-2.61
高:2.17
开:1.61
低:1.59
收:1.68
52周最高:2.86
52周最低:0.5100
股本:5,590.35万
流通股本:1,434.41万
量比:7.76
换手率:7.28%
股息:- -
股息率:- -
每股收益(TTM):-0.8133
每股收益(LYR):-0.2830
净资产收益率:-66.80%
总资产收益率:-38.67%
市净率:2.14
市盈率(LYR):-7.49

数据加载中...

2023/04/11

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/01/03

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/07/01

SEC问询函

CORRESP [Cover] - Correspondence
2022/07/01

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2022/06/17

SEC问询函

CORRESP [Cover] - Correspondence
2022/05/20

SEC问询函

CORRESP [Cover] - Correspondence
2022/03/31

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/25

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/25

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/15

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/14

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/06/07

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/03/29

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/03/19

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2021/03/18

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/03/17

SEC问询函

CORRESP [Cover] - Correspondence